10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
2026 Annual Meeting Results; Directors Elected and KPMG Ratified
Reg. FD
Annual Report to Security Holders
Sublease Agreement with First Tracks Biotherapeutics Executed
Change in Fiscal Year-End Approved by AnaptysBio Board
Announces First Quarter 2026 Financial Results and Provides Business Update
Annual Report Transition
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report